Literature DB >> 10792160

Long-term follow-up of noninvasive bladder tumours (stage Ta): recurrence and progression.

K Zieger1, H Wolf, P R Olsen, K Hojgaard.   

Abstract

OBJECTIVE: To evaluate long-term recurrence-free and progression-free survival of noninvasive bladder tumours (stage Ta), and the significance of simple risk factors, including concomitant epithelial dysplasia. PATIENTS AND METHODS: The study included 217 patients with primary noninvasive bladder tumour (stage Ta) who were followed routinely for up to 20 years. Voided urine cytology (VUC) and preselected site biopsies (PSB) were obtained prospectively to evaluate the significance of concomitant epithelial dysplasia.
RESULTS: The mean follow-up was 84 months (maximum 238). Of all tumours, 39% did not relapse, a further 20% recurred infrequently (less than once a year) and 41% recurred frequently, amongst which the most frequent were multiple and early recurrent tumours; 42 (19%) tumours progressed to stage T1+ and 23 (11%) progressed further (stage T2+ or metastases). No grade 1 tumours became invasive. Positive VUC or PSB, a short recurrence-free period or multiplicity, and size > 3 cm were significant predictive factors. The treatment and surveillance of epithelium-confined bladder tumours are discussed.
CONCLUSION: Concomitant dysplasia and early recurrence are associated with considerable risk of progression in the long-term follow-up in a group of otherwise low-risk superficial bladder tumours (stage Ta).

Entities:  

Mesh:

Year:  2000        PMID: 10792160     DOI: 10.1046/j.1464-410x.2000.00547.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  20 in total

1.  Histological grading of papillary urothelial carcinoma of the bladder: prognostic value of the 1998 WHO/ISUP classification system and comparison with conventional grading systems.

Authors:  J W A Oosterhuis; R F M Schapers; M L G Janssen-Heijnen; R P E Pauwels; D W Newling; F ten Kate
Journal:  J Clin Pathol       Date:  2002-12       Impact factor: 3.411

2.  Low-Grade, Multiple, Ta Non-muscle-Invasive Bladder Tumors: Tumor Recurrence and Worsening Progression.

Authors:  R B Nerli; Shridhar C Ghagane; K Shankar; Adarsh C Sanikop; Murigendra B Hiremath; Neeraj S Dixit; Laxman Magadum
Journal:  Indian J Surg Oncol       Date:  2018-01-29

Review 3.  [Follow-up of bladder cancer : The right examinations at the right time].

Authors:  P Olbert; P J Goebell; A Hegele
Journal:  Urologe A       Date:  2018-06       Impact factor: 0.639

4.  FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.

Authors:  Lucie C Kompier; Irene Lurkin; Madelon N M van der Aa; Bas W G van Rhijn; Theo H van der Kwast; Ellen C Zwarthoff
Journal:  PLoS One       Date:  2010-11-03       Impact factor: 3.240

Review 5.  Use of bacille Calmette-Guérin in superficial bladder cancer.

Authors:  J-P Meyer; R Persad; D A Gillatt
Journal:  Postgrad Med J       Date:  2002-08       Impact factor: 2.401

Review 6.  New and contemporary markers of prognosis in nonmuscle invasive urothelial cancer.

Authors:  M Hammad Ather; Syed M Nazim
Journal:  Korean J Urol       Date:  2015-07-31

7.  Long term follow-up in patients with initially diagnosed low grade Ta non-muscle invasive bladder tumors: tumor recurrence and worsening progression.

Authors:  Hiroaki Kobayashi; Eiji Kikuchi; Shuji Mikami; Takahiro Maeda; Nobuyuki Tanaka; Akira Miyajima; Ken Nakagawa; Mototsugu Oya
Journal:  BMC Urol       Date:  2014-01-08       Impact factor: 2.264

8.  Suppression of urinary bladder urothelial carcinoma cell by the ethanol extract of pomegranate fruit through cell cycle arrest and apoptosis.

Authors:  Song-Tay Lee; Min-Hua Lu; Lan-Hsiang Chien; Ting-Feng Wu; Li-Chien Huang; Gwo-Ing Liao
Journal:  BMC Complement Altern Med       Date:  2013-12-21       Impact factor: 3.659

9.  Size-based enrichment of exfoliated tumor cells in urine increases the sensitivity for DNA-based detection of bladder cancer.

Authors:  Elin Andersson; Kenneth Steven; Per Guldberg
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

10.  Clarification of the molecular pathway of Taiwan local pomegranate fruit juice underlying the inhibition of urinary bladder urothelial carcinoma cell by proteomics strategy.

Authors:  Ting-Feng Wu; Li-Ting Hsu; Bo-Xian Tsang; Li-Chien Huang; Wan-Yin Shih; Li-Yi Chen
Journal:  BMC Complement Altern Med       Date:  2016-03-09       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.